Curis Lifescien. (CURIS)
Score breakdown: P/E: 3/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹117.9 |
| Market Cap | ₹79.23 Cr |
| P/E Ratio | 9.67 |
| ROCE | 34.24% |
| ROE | —% |
| Dividend Yield | 0% |
| Profit Growth | 89.64% |
| Debt/Equity | — |
| Sales Growth | 75.53% |
| Promoter Holding | 68.03% |
| 52-Week Range | ₹83.6 — ₹234.75 |
| Sector | Pharmaceuticals & Biotechnology |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
When I look at Curis Lifescien, I try to ignore the market's daily mood and ask what the business earns on the money it uses. The figures here are intriguing but incomplete. The company earned a return on capital employed of 34.24%, which is excellent by any standards. A business that can compound capital at those rates deserves study. Sales have grown 75.53% and profits 89.64%; with a PEG of 0.12, the market is paying very little for this growth. At ₹117.90 with a market cap of only ₹79 crore, this is a small enterprise, and a P/E of 9.67 suggests either genuine bargain status or a quality discount.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer